1. The Market Imperative: Biologics Cost 46% of U.S. Drug Spend at Less Than 2% of Volume Biologic drugs generated […]

Section 1: The Patent as a Balance Sheet Asset A pharmaceutical patent is not a legal formality. It is the

Introduction: The End of the Free Pricing Era The pharmaceutical industry has long operated under a unique social contract: invest

1. Why Extrapolation Is the Most Valuable Two Words in Biosimilar Development Biologics occupy a peculiar place in the pharmaceutical

1. Introduction: The Economic Imperative of Valuation in Life Sciences The valuation of pharmaceutical and biotechnology entities constitutes one of

The New Economic Reality of Drug Manufacturing The days of selecting a Contract Development and Manufacturing Organization on the lowest

Introduction: The Market Paradox That Drives Every Deal The global generic drug industry has spent the last decade locked in

1. What Biopharma Intelligence Actually Does (and What Most Firms Think It Does) 1.1 The Operational Definition Biopharmaceutical business intelligence

1. Executive Summary Between now and 2032, an estimated 110 biological medicines in Europe will lose intellectual property protection, with